|
|||||
|
|

Tobacco company Philip Morris International (NYSE:PM) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 6.8% year on year to $10.36 billion. Its non-GAAP profit of $1.70 per share was in line with analysts’ consensus estimates.
Is now the time to buy PM? Find out in our full research report (it’s free for active Edge members).
Philip Morris’s fourth quarter results were driven by strong growth in its smoke-free portfolio, with management emphasizing double-digit volume gains for its IQOS, ZYN, and VIVE products across multiple regions. CEO Jacek Olczak called attention to the accelerated adoption of smoke-free alternatives, stating, “Our leading global position in smoke-free products enables us to deliver a fifth consecutive year of positive volumes.” Growth was broad-based, including notable gains in Europe, rapid expansion in new markets like Taiwan, and resilience in combustibles despite normalized industry declines and specific supply chain disruptions, particularly in Turkey.
Looking forward, the company’s guidance is shaped by ongoing investment in smoke-free innovation, regulatory developments—especially in the U.S. and Japan—and continued momentum for premium products. Management highlighted plans to launch new offerings, such as ZYN Ultra pending FDA approval, and anticipated excise tax increases in Japan, which are expected to pressure category growth temporarily. Olczak noted, “We target substantial further growth from IQOS in Japan in the years to come,” while also anticipating a significant acceleration in U.S. product launches, contingent on regulatory clearance.
Management attributed the latest quarter’s performance to the expanding smoke-free portfolio, efficient pricing strategies, and continued investment in emerging markets, while cautioning about upcoming regulatory and tax headwinds.
Philip Morris’s outlook centers on ongoing smoke-free product development, regulatory actions in key markets, and disciplined cost management to support margin expansion.
In the coming quarters, our analyst team will closely monitor (1) the pace of regulatory developments and product approvals for ZYN Ultra and IQOS ILUMA in the U.S., (2) the effect of Japanese excise tax increases on IQOS category growth and pricing elasticity, and (3) continued adoption rates of smoke-free products in emerging and established markets. Execution in digitalization and cost efficiency will also be crucial to sustaining margin progress.
Philip Morris currently trades at $182.44, in line with $182 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).
Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.
The names generating the next wave of massive growth are right here in our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
| Mar-09 | |
| Mar-09 | |
| Mar-09 | |
| Mar-08 | |
| Mar-08 | |
| Mar-05 | |
| Mar-05 | |
| Mar-04 | |
| Mar-04 | |
| Mar-02 | |
| Mar-02 | |
| Mar-01 | |
| Feb-28 | |
| Feb-27 | |
| Feb-27 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about Finviz Elite